To our knowledge, our work representsthe first study that engineered a probiotic bacterium to express andsecrete IFNL1 in a controllable manner, demonstrating its anti-inflammatoryeffects in in vitro IBD models. The gene discussed is IFNL1; the disease is inflammatory bowel disease.